@article{837a34a5ad2e4fc7a186556e0c780da4,
title = "GAL3 receptor knockout mice exhibit an alcohol-preferring phenotype",
abstract = "Galanin is a neuropeptide which mediates its effects via three G-protein coupled receptors (GAL1–3). Administration of a GAL3 antagonist reduces alcohol self-administration in animal models while allelic variation in the GAL3 gene has been associated with an increased risk of alcohol use disorders in diverse human populations. Based on the association of GAL3 with alcoholism, we sought to characterize drug-seeking behavior in GAL3-deficient mice for the first time. In the two-bottle free choice paradigm, GAL3-KO mice consistently showed a significantly increased preference for ethanol over water when compared to wildtype littermates. Furthermore, male GAL3-KO mice displayed significantly increased responding for ethanol under operant conditions. These differences in alcohol seeking behavior in GAL3-KO mice did not result from altered ethanol metabolism. In contrast to ethanol, GAL3-KO mice exhibited similar preference for saccharin and sucrose over water, and a similar preference for a high fat diet over a low fat diet as wildtype littermates. No differences in cognitive and locomotor behaviors were observed in GAL3-KO mice to account for increased alcohol seeking behavior. Overall, these findings suggest genetic ablation of GAL3 in mice increases alcohol consumption.",
keywords = "addiction, alcohol, galanin, galanin receptor-3",
author = "Genders, \{Shannyn G.\} and Scheller, \{Karlene J.\} and Jaehne, \{Emily J.\} and Turner, \{Bradley J.\} and Lawrence, \{Andrew J.\} and Brunner, \{Susanne M.\} and Barbara Kofler and \{van den Buuse\}, Maarten and Elvan Djouma",
note = "Funding Information: These studies were supported by the Research Focus Area, Understanding Disease at La Trobe University. SGG is supported by an Australian Government Research Training Program Scholarship. MvdB was supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia. BJT is supported by a NHMRC-ARC Dementia Research Leadership Fellowship (1137024) and the Stafford Fox Medical Research Foundation. The Florey Institute of Neuroscience and Mental Health acknowledge the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant. SMB was supported by the Austrian Research Promotion Agency (FFG, 822782/THERAPEP). ED conceived the project and designed the research; SGG, KJS, EJJ, BJT and ED performed the research; SGG, ED, EJJ and MvdB analyzed data. SMB and BK provided new transgenic animals. SGG and ED wrote the manuscript. All authors contributed to critical reading and editing of the manuscript. The authors declare no conflict of interest. Funding Information: These studies were supported by the Research Focus Area, Understanding Disease at La Trobe University. SGG is supported by an Australian Government Research Training Program Scholarship. MvdB was supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia. BJT is supported by a NHMRC-ARC Dementia Research Leadership Fellowship (1137024) and the Stafford Fox Medical Research Foundation. The Florey Institute of Neuroscience and Mental Health acknowledge the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant. SMB was supported by the Austrian Research Promotion Agency (FFG, 822782/THERAPEP). Publisher Copyright: {\textcopyright} 2018 Society for the Study of Addiction",
year = "2019",
month = sep,
doi = "10.1111/adb.12641",
language = "English",
volume = "24",
pages = "886--897",
journal = "Addiction Biology",
issn = "1355-6215",
publisher = "Wiley-Blackwell",
number = "5",
}